Filing summary
Entity discrepancy: The supplied filing is Jupiter Wellness, Inc.’s Form 10-Q for the quarter ended September 30, 2020, not BONK, INC. The summary below reflects the filing text.
Business context and reporting period
Jupiter Wellness describes itself as an early-stage CBD consumer-products and product-development company, with CaniSun, CaniSkin and CaniDermRX brands. The unaudited report covers the three and nine months ended September 30, 2020, compared with the same 2019 periods. In February 2020, it acquired Magical Beasts, LLC, adding products and sales and marketing capabilities; it also began selling hand sanitizer and pandemic-related supplies.
Financial results and position
- Revenue: Third-quarter sales were $178,335, versus $5,068 in 2019. Nine-month sales were $753,729, versus $6,399.
- Gross profit and margin: Third-quarter gross profit was $81,727 (about 45.8% margin), versus $1,946 (about 38.4%). Nine-month gross profit was $320,424 (about 42.5%), versus $1,327 (about 20.7%).
- Losses: Net loss was $607,289 for the quarter and $1,522,462 for the nine months, compared with $127,896 and $270,464, respectively, in 2019. Nine-month loss per share was $0.22, versus $0.04.
- Expenses: Nine-month operating expenses were $1,750,778, up from $270,927; the company also recorded $92,108 in net other expense, principally interest. Management cited increased payroll and general and administrative costs, professional fees, and depreciation and amortization.
- Cash flow: Nine-month operating cash use was $1,315,100; investing cash use was $289,391, including $245,391 of net cash paid in the acquisition. Financing provided $1,204,578. Cash fell from $531,026 at year-end 2019 to $131,113 at September 30, 2020.
- Liquidity and equity: Current assets were $535,208 and current liabilities $2,526,844, implying a working-capital deficit of about $2.0 million. Shareholders’ deficit was $790,997.
- Debt: The balance sheet reported $1,375,000 of related-party convertible notes and a $985,475 acquisition note, net of discount. It also reported an $84,578 SBA loan balance. Total liabilities were $2,556,982.
Changes versus prior period
Sales rose sharply from a very low 2019 base as the company expanded marketing and distribution, acquired Magical Beasts, added product lines, and introduced sanitizer. Losses and expenses also increased substantially. The acquisition added $884,295 of net intangible assets and $308,690 of goodwill at September 30, 2020, alongside the acquisition note payable.
Outlook, risks, contingencies and unusual items
- Funding outlook: Management said it expected continued significant losses, but that post-quarter IPO proceeds would provide capital sufficient for at least 24 months. On November 3, 2020, the company completed an IPO with approximately $5.9 million in net proceeds. The filing also describes proceeds as approximately $6.0 million in its going-concern discussion.
- Development and regulation: The company planned clinical and development work for eczema and other dermatological products. It estimated approximately $120,000 for initial studies and $250,000 for development studies; COVID-19 delayed development work. Clinical efficacy, FDA requirements, and the ability to commercialize products remain uncertain.
- Going concern and financing risk: At quarter-end, cash was low relative to operating cash use, and the company had a substantial accumulated deficit and working-capital shortfall. Management warned that inability to generate cash or raise additional capital could force it to curtail or cease operations, and future financing could dilute shareholders.
- Debt and subsequent equity activity: After quarter-end, a holder converted $300,000 of notes into 100,000 shares. Warrants were exercised for $444,000 cash, with additional cashless exercises. Shares outstanding rose from 6,893,000 at September 30 to 9,032,333 at November 16, 2020, including IPO and service shares.
- Contingencies: A settlement concerning a judgment against Magical Beasts directed the first $334,000 of the amount payable to its former owner to the plaintiff; the company said this would reduce the acquisition note rather than add a financial-statement impact. Separately, Jupiter and certain affiliated parties were litigating claims over alleged entitlement to company shares; the filing describes counterclaims and a pending motion but does not establish an outcome.
- Controls: Management concluded disclosure controls were not effective, citing inadequate segregation of duties and incomplete accounting-procedure documentation. It reported no material control changes during the quarter.
- Guidance: The filing provides no revenue, earnings, or other quantified financial guidance.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for Jupiter Wellness, Inc., notwithstanding the BONK, INC. request metadata.
- Reconcile the stated post-IPO net proceeds ($5.9 million versus approximately $6.0 million) and verify cash available after subsequent debt payments and other uses.
- Review the terms, maturity, related-party status, and post-quarter settlement or conversion of the convertible notes and acquisition note.
- Track operating cash burn, working-capital needs, product sales by source, and the company’s ability to sustain revenue growth while controlling expenses.
- Assess clinical-study progress, COVID-related delays, regulatory requirements, and the evidence supporting product claims.
- Monitor the unresolved litigation and remediation of the disclosed material weaknesses in financial reporting controls.